scholarly journals Busulfan, Melphalan, and Thiotepa Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) of Pediatric Patients with Acute Leukemia and Central Nervous System (CNS) Disease

2014 ◽  
Vol 20 (2) ◽  
pp. S169
Author(s):  
Christopher J. Forlenza ◽  
Rachel Kobos ◽  
Nancy A. Kernan ◽  
Andromachi Scaradavou ◽  
Susan E. Prockop ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Acute Leukemia ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Pediatric Patients ◽  
Hematopoietic Stem

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children

2019 ◽  
Vol 142 (4) ◽  
pp. 217-223
Author(s):  
Peng Ke ◽  
Xiebing Bao ◽  
Jihao Zhou ◽  
Qian Zhu ◽  
Juan Zhuang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Impact On Survival ◽  
Poor Outcomes

Central nervous system complications (CNSCs) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are common and may be a significant source of morbidity and mortality. We performed a retrospective study of 153 pediatric patients who underwent allo-HSCT to determine CNSC type, incidence, and impact on survival. A total of 34 patients (22.2%) developed CNSCs. The cumulative incidence of CNSCs at 100 days and 3 years was 18.30 and 22.73%, respectively. The most common CNSC was calcineurin inhibitor (CNI)-associated neurotoxicity (50.0%). Risk factors for CNSCs were the time from diagnosis to HSCT ≥4.8 months (p = 0.032) and the development of acute graft-versus-host disease (aGVHD) grade III–IV (p = 0.002). CNSCs after allo-HSCT negatively impacted overall survival (hazard ratio [HR] 1.97, p = 0.043) and nonrelapse mortality (HR 4.84, p < 0.001). In conclusion, CNSCs after allo-HSCT are associated with poor outcomes; patients with severe aGVHD and/or late transplantation should be given more attention.

scholarly journals Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma

Haematologica ◽  
2019 ◽  
Vol 105 (4) ◽  
pp. e160-e163 ◽  
Author(s):  
Thomas Mika ◽  
Swetlana Ladigan ◽  
Alexander Baraniskin ◽  
Deepak Vangala ◽  
Sabine Seidel ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Central Nervous System Lymphoma ◽  
Hematopoietic Stem
Sign in / Sign up

Export Citation Format

Share Document